Citadel Advisors’s Century Therapeutics IPSC Stock Holding History
Bought
Maintained
Sold
Other funds holding IPSC
Citadel Advisors's IPSC Position: Q3 2026 in Review
Citadel Advisors reduced its Century Therapeutics (IPSC) stake by 33% in Q3 2026, selling an estimated $85.6K and leaving 84,660 shares worth $145K. The position accounts for ﹤0.01% of the portfolio, ranked #12616.
Citadel Advisors first reported a position in IPSC in Q3 2021 and has held it in 18 quarters since. The position peaked at $673K in Q4 2022. 102 funds tracked by Wall St. Rank hold IPSC as of Q3 2026.
- Citadel Advisors held 84,660 shares of Century Therapeutics worth $145K as of Q3 2026.
- Citadel Advisors sold 41,810 Century Therapeutics shares in Q3 2026, an estimated $85.6K.
- Century Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #12616 holding.
- Citadel Advisors first reported a position in Century Therapeutics in Q3 2021 and has held it in 18 quarters since.
- Citadel Advisors's Century Therapeutics position peaked at $673K in Q4 2022.
- 102 funds tracked by Wall St. Rank held Century Therapeutics as of Q3 2026.
Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.